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Background: Recent guidelines suggest the adoption of regional citrate anticoagulation (RCA) as first choice CRRT
anticoagulation modality in patients without contraindications for citrate. Regardless of the anticoagulation
protocol, hypophosphatemia represents a potential drawback of CRRT which could be prevented by the adoption
of phosphate-containing CRRT solutions. The aim was to evaluate the effects on acid–base status and phosphate
supplementation needs of a new RCA protocol for Continuous Venovenous Hemodiafiltration (CVVHDF) combining
the use of citrate with a phosphate-containing CRRT solution.
Methods: To refine our routine RCA-CVVH protocol (12 mmol/l citrate, HCO3
- 32 mmol/l replacement fluid) (protocol A)
and to prevent CRRT-related hypophosphatemia, we introduced a new RCA-CVVHDF protocol (protocol B) combining
an 18 mmol/l citrate solution with a phosphate-containing dialysate/replacement fluid (HCO3
- 30 mmol/l, Phosphate
1.2). A low citrate dose (2.5–3 mmol/l) and a higher than usual target circuit-Ca2+ (≤0.5 mmol/l) have been adopted.
Results: Two historical groups of heart surgery patients (n = 40) underwent RCA-CRRT with protocol A (n = 20, 102
circuits, total running time 5283 hours) or protocol B (n = 20, 138 circuits, total running time 7308 hours). Despite higher
circuit-Ca2+ in protocol B (0.37 vs 0.42 mmol/l, p < 0.001), circuit life was comparable (51.8 ± 36.5 vs 53 ± 32.6 hours).
Protocol A required additional bicarbonate supplementation (6 ± 6.4 mmol/h) in 90% of patients while protocol B
ensured appropriate acid–base balance without additional interventions: pH 7.43 (7.40–7.46), Bicarbonate 25.3 (23.8–26.6)
mmol/l, BE 0.9 (−0.8 to +2.4); median (IQR). No episodes of clinically relevant metabolic alkalosis, requiring modifications
of RCA-CRRT settings, were observed. Phosphate supplementation was needed in all group A patients (3.4 ± 2.4 g/day)
and in only 30% of group B patients (0.5 ± 1.5 g/day). Hypophosphatemia developed in 75% and 30% of group A and
group B patients, respectively. Serum phosphate was significantly higher in protocol B patients (P < 0.001) and, differently
to protocol A, appeared to be steadily maintained in near normal range (0.97–1.45 mmol/l, IQR).
Conclusions: The proposed RCA-CVVHDF protocol ensured appropriate acid–base balance without additional
interventions, providing prolonged filter life despite adoption of a higher target circuit-Ca2+. The introduction of a
phosphate-containing solution, in the setting of RCA, significantly reduced CRRT-related phosphate depletion.
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Continuous renal replacement therapy (CRRT) is the
most widely adopted technique for the treatment of
acute kidney injury (AKI) in the critically ill [1-3] and it
is well known that the need for prolonged anticoagula-
tion still represents its main drawback [4-6]. Indeed, al-
though the incidence of bleeding complications in
patients undergoing renal replacement therapy (RRT)
can be extremely variable among different studies, the
risk of major bleeding during standard anticoagulation
with heparin should be strongly considered [5,7]. Among
different options, regional citrate anticoagulation (RCA)
has been increasingly suggested as a safe and efficacious
alternative to standard heparin anticoagulation during
CRRT [8-19].
Citrate provides anticoagulation in the extracorporeal
circuit by chelation of ionized calcium [8], which is re-
quired as a key cofactor in several steps of the clotting
cascade [20]. A citrate solution is infused before the fil-
ter, being the citrate dose titrated to maintain ionized
calcium levels in the extracorporeal circuit below 0.3–
0.4 mmol/l. Part of the infused citrate is removed by the
treatment itself, depending on its operative settings; cit-
rate returning to the patient is rapidly metabolized by
the liver and the skeletal muscle in the Krebs’ cycle, with
an ensuing bicarbonate production which provides a
buffer supply to the patient [8]. On these bases, the cit-
rate metabolic load for the patient is the difference be-
tween the delivered dose of citrate and the amount of
citrate lost in the effluent [21]. Therefore, different com-
binations of citrate solutions and replacement fluids for
CRRT, as well as the operational parameters setting pe-
culiar of each RRT modality, might be associated with a
high variability of buffers supply, thus significantly af-
fecting the acid–base status of the patient [22-24].
Hypophosphatemia is a known issue of CRRT reported
in up to 80% of cases when standard CRRT solutions are
used [25-30], especially if high dialysis doses are deliv-
ered [26,27]. RRT-related phosphate depletion should be
avoided in critically ill patients and the adoption of
phosphate-containing CRRT solutions could be helpful
to reduce the incidence of hypophosphatemia and/or to
minimize the need for parenteral phosphorus supple-
mentation [24,25,28,30,31].
In the present study we evaluated the effects on acid–
base status and serum phosphate levels of a new RCA
protocol for Continuous Venovenous Hemodiafiltration
(CVVHDF) using an 18 mmol/l citrate solution in com-
bination with a phosphate-containing solution, acting as
dialysate and replacement fluid. The new protocol was
introduced with the following targets: a) to refine buffers
balance of a previously adopted RCA protocol for Con-
tinuous Venovenous Hemofiltration (CVVH), based on a
12 mmol/l citrate solution combined with a conventionalreplacement fluid; b) to prevent CRRT-related phosphate
depletion; c) to maintain a low citrate dose, adopting a
higher than usual target circuit ionized calcium.
Methods
In this observational study, data prospectively collected
from May 2010 to December 2012 have been analysed
to compare a previously adopted RCA-CVVH protocol
with a newly designed RCA-CVVHDF protocol in two
historical groups of patients who consecutively under-
went CRRT for AKI following major heart surgery at
the Cardiac Surgery ICU of Policlinico Umberto I,
“Sapienza” University (Rome, Italy). Only patients
treated for at least 72 hours have been included in the
analysis. The study was in agreement with the Declar-
ation of Helsinki and informed consent was obtained
from either the patient or a close relative. Ethics Com-
mittee approval was not required for this observational
study because the patients, included in a retrospective
analysis of prospectively collected data, were not discre-
tionally assigned to different medical interventions. In-
deed, in this study we report, in two groups of patients
who underwent RCA-CRRT in subsequent historical pe-
riods, the effects of the change of our routine RCA
protocol after commercial availability of new solutions,
registered in our country for specific use in CRRT. At
our institution, RCA is the standard anticoagulation
method in high bleeding risk heart surgery patients
undergoing CRRT and data collection, as well as RCA
protocols, are part of our routine medical procedures.
Starting from April 2012, according to KDIGO Clinical
Practice Guideline for AKI [6] and regardless of the co-
agulation status, the adoption of RCA was extended to
all patients undergoing CRRT without contraindications
for citrate.
Until September 2011, RCA was performed in CVVH
modality with a 12 mmol/l pre-dilution citrate solution
(trisodium citrate 10 mmol/l, citric acid 2, Na+ 136, Cl-
106; Prismocitrate 10/2, Gambro, Sondalo, Italy) and a
calcium-containing post-dilution replacement fluid with
bicarbonate (HCO3
- 32 mmol/l, Ca2+ 1.75, Mg2+ 0.5, K+
2, Na+ 140, Cl- 111.5; Prismasol 2, Gambro, Sondalo,
Italy) (Protocol A) (Figure 1) [19]. In case of worsening
metabolic acidosis, not related to citrate accumulation
and persisting after RCA-CVVH parameters optimiza-
tion, additional bicarbonate infusion in a separate line
was started according to ICU physician’s judgement. In
order to optimize buffers balance and to possibly reduce
the need for phosphorus supplementation, we imple-
mented a new protocol (Protocol B) adopting the follow-
ing solutions, recently introduced in Europe: 18 mmol/l
pre-dilution citrate solution (trisodium citrate 18 mmol/
l, Na+ 140, Cl- 86; Prismocitrate 18/0, Gambro) com-
bined with a calcium- and phosphate-containing
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Figure 1 Pre-post dilution RCA-CVVH and RCA-CVVHDF circuits. Schematic representation of the RCA extracorporeal circuits reporting the
composition of the solutions respectively adopted in protocol A (top panel) and protocol B (bottom panel).
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placement fluid (HPO4
2- 1.2 mmol/l, HCO3
- 30, Ca2+
1.25, Mg2+ 0.6, K+ 4, Na+ 140, Cl- 115.9; Phoxilium,
Gambro) (Figure 1). The CVVHDF modality has been
preferred with the aim to maintain a low filtration frac-
tion. The protocol has been designed through a math-
ematical model developed to roughly estimate metabolic
citrate load, buffers balance (citrate and bicarbonate), ef-
fluent calcium loss, as well as the main RCA-CRRT pa-
rameters. The model, included in a database software
(FileMaker Inc, Santa Clara, CA, USA), and compatible
with many portable devices, allowed to easily making
calculations at the bedside. Input fields: blood flow rate
(ml/min), citrate solution concentration (mmol/l), citratesolution flow rate (l/h), bicarbonate and ionized calcium
dialysate and/or replacement solution concentration
(mmol/l), dialysate flow rate (l/h), post-dilution flow rate
(l/h), patient’s bicarbonate and ionized calcium (mmol/l),
patient’s hematocrit (%) and serum protein (g/dl), net
ultrafiltration rate (l/h). Calculated output fields (cor-
rected for pre-dilution when appropriate): pre-filter esti-
mated citrate blood concentration (mmol/l) calculated in
plasma water [(citrate solution concentration × citrate
flow rate)/(citrate flow rate + plasma water flow rate)],
total effluent rate (l/h), filtration fraction (%), estimated
citrate metabolic load (mmol/h) [(citrate solution con-
centration × citrate flow rate) – (effluent rate × estimated
citrate blood concentration × SC)], CRRT buffers and
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(ml/h).
CRRT was performed using the Prismaflex system
(Gambro Lundia AB, Lund, Sweden) and PAES hemofil-
ters (HF 1000, 1.15 m2, Gambro, Meyzieu, France). Vas-
cular access was obtained by cannulation of the internal
jugular or femoral vein with a double lumen polyureth-
ane catheter (⊘ 12 French). In relation to blood flow
rate, the citrate solution flow rate was initially set to
meet a roughly estimated target circuit citrate concen-
tration of 2.5–3 mmol/l, calculated in plasma water
[32,33]. For protocol A, citrate flow rate was modified, if
needed, to achieve a circuit Ca2+ (c-Ca2+) ≤0.4 mmol/l.
For protocol B, taking into account the combination of a
more concentrated citrate solution with a 30 mmol/l bi-
carbonate dialysate/replacement fluid, we accepted a
higher than usual c-Ca2+ target of ≤0.5 mmol/l with the
aim to maintain a low citrate dose and to prevent the
occurrence of metabolic alkalosis related to buffer over-
load. In protocol B (CVVHDF), dialysate flow was main-
tained at the fixed rate of 500 ml/h. Post-dilution flow
rate (Prismasol 2 for protocol A, Phoxilium for protocol
B) was adjusted to achieve a prescribed dialysis dose,
corrected for pre-dilution [correction factor = blood flow
rate/(blood flow rate + Pre-dilution infusion rate)], of at
least 25 ml/kg/h. Calcium chloride (10%) was infused in
a separate central venous line to maintain a target sys-
temic Ca2+ (s-Ca2+) of 1.1–1.25 mmol/l, measured by ar-
terial blood gases at least every 4 hours. A total calcium/
Ca2+ ratio (Calcium Ratio) > 2.5 was considered an indir-
ect sign of citrate accumulation [34]. Serum electrolytes,
coagulation parameters and complete blood count were
daily assessed.
By convention, hypophosphatemia was defined as fol-
lows: mild (<0.81 mmol/l), moderate (<0.61 mmol/l) and
severe (<0.32 mmol/l) [30]. Nutritional support was pro-
vided mainly via parenteral route associated, if tolerated,
with enteral route; energy and protein intake targets
were 25 Kcal/Kg/day and 1.5 g/Kg/day with a phos-
phorus intake of about 20–30 mmol/day during both
protocol periods. Potassium, phosphate and magnesium
losses with CRRT were replaced, when needed, respect-
ively with potassium chloride, d-fructose-1,6-diphos-
phate (FDP; Esafosfina® 5 g/50 ml) and magnesium
sulphate. In particular, FDP administration was sched-
uled in case of phosphate levels <0.9 mmol/l. Acid–base
parameters, K+ and Ca2+ were measured by arterial
blood gases analyzer (GEM Premiere 4000, Instrumenta-
tion Laboratory UK Ltd, Warrington, UK) at least every
4 hours. Clinically relevant metabolic alkalosis was arbi-
trarily defined as a persistent increase of pH >7.50 and
bicarbonate >30 mmol/l.
The causes for CRRT stopping were reported after an
accurate evaluation of monitor events and pressurealarms, recorded on the Prismaflex memory card. CRRT
interruption due to coagulation was defined as an overt
sign of circuit clotting, or as a 100% increase of filter drop
pressure (difference between pre-filter and post-filter
hydrostatic pressure). CRRT interruption for clinical rea-
sons (i.e., evaluation of renal function recovery, patient
mobilization, etc.), unrelated to circuit clotting, was classi-
fied and reported as scheduled CRRT stopping.
Statistical analysis
Data are reported as mean ± standard deviation (SD) or
as median and interquartile range (IQR). Statistical ana-
lysis for continuous variables was made by one-way
ANOVA or Student t-test. Non-parametric analysis was
performed, when appropriate, using the Mann–Whitney
U test for independent samples. Categorical variables
were analysed with chi-square test or Fisher exact test.
Circuit lifetime was evaluated with Kaplan-Meier sur-
vival analysis and survival curves distribution was com-
pared with the Log Rank (Mantel-Cox) test. All tests
were 2-sided (significance level 5%). IBM SPSS statistical
software (19.0, SPSS Inc., USA) was used for all analysis.
Results
Twenty patients underwent RCA-CVVH with protocol A
while, after introduction of the new protocol, 20 patients
were treated with RCA-CVVHDF according to protocol
B. Clinical characteristics of the patients at the time of
starting CRRT have been compared and reported for
both groups in Table 1. Among RCA-CRRT initial pa-
rameters, reported in Table 2, prescribed dialysis dose,
corrected for pre-dilution, as well as citrate dose, were
comparable.
One hundred and two circuits (total running time
5283 hours) were used during protocol A period while
138 circuits (total running time 7308 hours) were used
after adoption of protocol B. Filter life was 51.8 ± 36.5
and 53 ± 32.6 hours, respectively (P = 0.796) (Table 3).
RCA-CRRT stopping causes and circuits running at
24, 48, 72 hours are reported in Table 3. Considering all
circuits (n = 240), filter clotting was the less frequent
cause for RCA-CRRT interruption (3.7%). In particular,
during protocol A, RCA-CVVH didn’t stop in any case
for filter clotting while 6.5% of protocol B CRRT sessions
were stopped for significant increments of filter drop
pressure (>100%) (P = ns). Overall, pressure alarms
handling, related to CVC malfunction, was the most fre-
quent cause of CRRT stopping (37.1%). Kaplan-Meier
curves of circuit lifetime probability, derived from ana-
lysis of scheduled and unscheduled CRRT stoppings for
any cause, showed no difference between the two proto-
cols (Figure 2).
Calcium monitoring parameters, including c-Ca2+,
s-Ca2+ and Calcium Ratio for each patient at different






Female gender 7/20 (35%) 4/20 (20%) 0.480
Age, years 72 (69–77) 70 (59–73) 0.073
Body weight, kg 72 (67–79) 70 (66–80) 0.715
Oliguric AKI § 90% 75% 0.407
Mean arterial pressure, mmHg 70 (70–80) 70 (62–80) 0.399
Use of vasopressors or inotropes 75% 85% 0.695
Mechanical ventilation 85% 90% 0.633
Artificial nutrition 95% 100% 0.311
APACHE II score 32 (29–35) 32 (27–35) 0.307
SOFA score 15 (12–16) 13 (9–14) 0.056
SOFA cardio-vascular score 3 (2–3) 3 (2–3) 0.130
Serum creatinine, mg/dl 2.10 (1.75–3.00) 2.25 (1.75–2.85) 0.469
Blood urea nitrogen, mg/dl 40.5 (26.9–62.0) 40.5 (29.0–55.2) 0.978
Hemoglobin, g/dl 10.9 (9.9–11.2) 10.0 (8.8–10.9) 0.084
Hematocrit,% 32.1 (31.2–33.4) 31.6 (27.5–34.5) 0.419
White blood cells, ×103/μl 11.0 (8.2–15.9) 12.4 (11.0–16.5) 0.664
Platelet count, ×103/μl 93 (76–177) 161 (98–254) 0.043
Antithrombin III activity,% 70 (63–78) 61 (49–78) 0.250
APTT Ratio 1.4 (1.3–1.9) 1.6 (1.4–2) 0.358
Sodium, mmol/l 139 (134–140) 139 (137–143) 0.110
Potassium, mmol/l 4.3 (4.0–4.8) 4.2 (4.1–4.8) 0.762
Total Calcium, mmol/l 2.16 (1.95–2.30) 2.03 (1.93–2.19) 0.166
Phosphorus, mmol/l 1.40 (1.07–1.58) 1.38 (1.16–1.70) 0.897
Magnesium, mmol/l 0.85 (0.75–0.93) 0.78 (0.74–0.97) 0.572
pH, units 7.38 (7.35–7.41) 7.40 (7.38–7.43) 0.324
Bicarbonate, mmol/l 21.8 (21.0–22.6) 22.2 (21.0–24.2) 0.535
Base Excess −3.5 (−4.0 to −2.0) −1.0 (−4.0 to 1.0) 0.316
pCO2, mmHg 38 (36–42) 37 (33–40) 0.992
Lactate, mmol/l 1.4 (1.0–3.0) 1.4 (1.2–2.4) 0.879
Bilirubin, mg/dl 0.89 (0.62–1.45) 0.73 (0.46–1.37) 0.376
Aspartate aminotransferase, IU/l 89 (29–608) 97 (49–376) 0.800
Alanine aminotransferase, IU/l 37 (12–325) 26 (18–75) 0.970
Albumin, g/dl 2.6 (2.4–2.8) 2.45 (2.2–2.9) 0.820
Heart surgery: Overall
Coronary artery bypass grafting 25% 35% 30%
Coronary artery bypass
grafting + valvular surgery
40% 15% 27.5%
Valvular surgery 25% 20% 22.5%
Ascending aorta replacement 10% 30% 20%
Data are expressed as median (IQR) or percentage. § According to AKIN criteria
(Crit Care 2007; 11:R31).
Table 2 Initial RCA-CRRT settings
RCA-CRRT settings Protocol A Protocol B P-value
Prescribed dialysis dose§,
ml/kg/h
28.25 (26.69–29.66) 26.67 (25.69–28.88) 0.333
Blood flow rate, ml/min 130 (130–140) 140 (140–140) 0.083
Pre-dilution citrate solution
flow rate, l/h
1.56 (1.50–1.68) 1.00 (1.00–1.00) <0.001
Pre-dilution,% 16.67 (16.58–16.67) 10.64 (10.64–10.64) <0.001
Post-dilution replacement
fluid flow rate, l/h
0.80 (0.80–0.95) 0.60 (0.55–0.80) <0.001
Dialysate flow rate, l/h N/A 0.50 (0.50–0.50) -
Filtration Fraction,% 38.4 (34.5–40.3) 27.0 (25.7–28.8) <0.001
10% Calcium chloride infusion
rate, mmol/h
2.00 (1.60–2.10) 1.90 (1.36–2.28) 0.344
Citrate infusion rate, mmol/h 18.70 (18.00–20.15) 18.00 (18.00–18.00) 0.051
Estimated citrate load, mmol/h 12.34 (11.74–13.92) 12.35 (12.05–12.65) 0.471
Estimated citrate dose, mmol/l 2.84 (2.74–2.91) 2.83 (2.76–2.95) 0.618
Data are expressed as median (IQR). § Corrected for pre-dilution.








Mean ± SD, h 51.8 ± 36.5 53 ± 32.6 52.5 ± 34.2
Median (IQR), h 44.5 (24.0–72.0) 47.5 (24.0–78.5) 47.5 (24.0–75.0)
> 24 h 77% 76% 76.7%
> 48 h 50% 50% 50%
> 72 h 28% 33% 31.2%
CRRT STOPPING CAUSES
CVC malfunction, n (%) 40 (39.2%) 49 (35.5%) 89 (37.1%)
Alarm handling/ technical
issues, n (%)
26 (25.4%) 31 (22.5%) 57 (23.8%)
Scheduled, n (%) 24 (23.6%) 36 (26.1%) 60 (25%)
Medical procedures, n (%) 12 (11.8%) 13 (9.4%) 25 (10.4%)
Clotting, n (%) 0 (0%) 9 (6.5%) 9 (3.7%)
Data are expressed as mean ± SD or median (IQR) or percentage.
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was maintained in the target range adopted for protocol
A and protocol B and was significantly higher during
RCA-CVVHDF with protocol B (median 0.37 vs
0.42 mmol/l, P < 0.001) (Table 4). With both protocols,
s-Ca2+ was steadily maintained in normal range with few
modifications of CaCl2 flow rate (1–2 within 24 hours),without episodes of hypocalcemia or hypercalcemia
(Figure 3). The amount of CaCl2 required to maintain
s-Ca2+ in the target range was comparable (P = 0.800)
(Table 4).
Acid–base parameters and the main serum electrolytes
for both groups of patients are reported in Table 4.
Serum bicarbonate levels and pH values were signifi-
cantly higher in protocol B patients (P < 0.001), without
the need for additional bicarbonate infusion, which was
otherwise required in 18 out of 20 protocol A patients
(NaHCO3 infusion rate 6 ± 6.4 mmol/h). No episodes of
clinically relevant metabolic alkalosis, requiring add-
itional intervention on RCA-CRRT settings, were ob-
served with both protocols. In particular, during protocol
B, pH values resulted ≥7.50 in 3.8% of determinations
(63 out of 1664) with a Base Excess ≥5 in 3.2% of deter-
minations (54 out of 1664). Acid–base parameters
SigdfChi-square
Log Rank (Mantel-Cox)         ,7541,098
censored
Figure 2 Kaplan-Meier curves of circuit lifetime probability
according to the two RCA protocols. Survival curves, derived from
the analysis of scheduled and unscheduled CRRT stopping for any cause,
have been compared with the Log Rank (Mantel-Cox) test (p = 0.754).
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carbonate and Base Excess for each patient at different
treatment days, are displayed in Figure 4. Regardless of
the RCA-CRRT protocol, no episodes of metabolic acid-
osis, possibly related to inadequate citrate metabolism,
were observed and Calcium Ratio resulted constantly
below the accepted threshold value of 2.5.
At some times during RCA-CRRT, 75% of protocol A
patients developed hypophosphatemia (6 mild, 9 moder-
ate), otherwise observed in only 30% of protocol B pa-
tients (4 mild, 2 moderate) (P < 0.001). In particular, 89
out of 206 phosphorus level determinations met the def-
inition criteria for mild to moderate hypophosphatemia
during protocol A (42 mild, 47 moderate) while a signifi-
cantly lower number of determinations (26 out of 334;
P < 0.001) revealed episodes of hypophosphatemia dur-
ing protocol B (19 mild, 7 moderate). Protocol A required
phosphorus supplementation (FDP 3.39 ± 2.45 g/day) in
all patients. A lower amount of phosphorus supplemen-
tation (FDP 0.52 ± 1.53 g/day) was needed in 6 out of 20
patients (30%) undergoing protocol B. Serum phosphate
was significantly higher in protocol B patients (P < 0.001)
and, differently to protocol A, it appeared to be steadily
maintained in near normal range (IQR 0.97–1.45 mmol/l)
without episodes of hyperphosphatemia requiring modifi-
cations of CRRT settings (Table 4). Serum phosphate levels
throughout RCA-CRRT days are displayed in Figure 5 for
both protocols.
Clinically relevant hypomagnesemia has been prevented
in all patients by magnesium sulphate supplementation
(2 to 3 g/day) (Table 4). Serum potassium was steadily
maintained in normal range with both protocols. As ex-
pected, the need for potassium chloride supplementation
was significantly lower with protocol B (P < 0.001) (Table 4).During RCA-CRRT no patients had bleeding compli-
cations and overall transfusion rate was 0.33 ± 0.23 blood
units/day (median 0.24, IQR 0.18–0.43), without differ-
ences between the two groups (0.32 ± 0.2 versus 0.33 ±
0.26, P = 0.704). Overall, thirty-day survival was 67.5%
while survival at discharge from the hospital was 57.5%.
At the time of discharge, renal function recovery, allow-
ing to stop RRT, was observed in 9 out of 11 survivors
of protocol A patients (81.8%) and in 10 out of 12 survi-
vors of protocol B patients (83.3%).
Discussion
The need for continuous anticoagulation represents a
potential drawback of CRRT modalities [4-6]. Recently
published guidelines suggest the adoption of RCA as
first choice CRRT anticoagulation modality in patients
without contraindications for citrate, especially in the
presence of increased bleeding risk [6].
At our institution, RCA is now routinely adopted in
heart surgery patients undergoing CRRT with the aim to
minimize bleeding complications. In the present study,
both RCA protocols allowed to maintain low transfusion
rates in a small cohort of selected high bleeding risk pa-
tients, ensuring an adequate filter life with a very low in-
cidence of clotting as cause of CRRT stopping (9 out of
240 CRRT sessions). In particular, the use of a low flow
rate calcium-containing dialysate, which characterizes
protocol B, didn’t appear to adversely affect mean filter
life. Regarding the clotting events observed in a small
proportion of protocol B circuits, it is tempting to
speculate that this finding could be explained by the
strategy to allow higher levels of Ca2+ inside the circuit,
although the possible role of the significantly higher
platelet count should be considered. On the other side,
this potential drawback of protocol B could be counter-
balanced by the advantage of a more easy maintenance
of a low citrate dose (2.5–3 mmol/l in plasma water). In
this regard, taking into consideration that any strategy
aimed to prevent citrate accumulation should be tar-
geted to decrease citrate infusion rate [35], both proto-
cols have been designed with the aim to minimize
citrate load, with a resulting citrate dose among the low-
est until now reported. Regardless of the RCA protocol
adopted, no episodes of high anion gap metabolic acid-
osis, possibly related to inadequate citrate metabolism,
were observed. Indeed, the Calcium Ratio, commonly
accepted as a useful index of citrate accumulation
[34,36,37] and recently reported as an independent pre-
dictor of clinical outcome [38], resulted steadily below
the conventional threshold value of 2.5 in all patients. On
the other hand, the buffers mass balance obtained with
protocol A, based on a 12 mmol/l citrate solution, was fre-
quently associated with a suboptimal buffers supply des-
pite optimization of RCA-CVVH operative parameters.
Figure 3 Systemic ionized calcium (s-Ca2+), circuit ionized calcium (c-Ca2+) and Calcium Ratio throughout RCA-CRRT days with the two
different protocols. Data for protocol A (left panels) and protocol B (right panels) are displayed as median and interquartile range (q1 to q3). ** p < 0.02.
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http://www.biomedcentral.com/1471-2369/14/232For this reason, additional bicarbonate infusion was re-
quired in most of the patients (90%). Thus, in our experi-
ence, the combination of a very low citrate concentration
solution (10 mmol/l trisodium citrate, 2 mmol/l citric
acid) with a conventional bicarbonate replacement fluid
(32 mmol/l) does not allow to tailor buffer delivery ac-
cording to patient’ needs. This problem cannot be easily
overcome by an increase of pre-dilution citrate flow rate,
which invariably results in a significant increase of effluentrate with the consequent loss of more citrate and bicar-
bonate in the ultrafiltrate. Thus, any increment in citrate
dose does not result in a clinically significant increment of
buffers delivery to the patient. Comparable findings, re-
garding the persistence of mild metabolic acidosis and the
need for additional bicarbonate, have been reported by
Hetzel et al., performing CVVH with a 13 mmol/l citrate
solution [18], and by Shum et al., adopting CVVH with a
12 mmol/l citrate solution combined with pre-filter
Table 4 Laboratory variables and supplementation needs during RCA-CRRT
Variable Protocol A (n = 20) Protocol B (n = 20) P value
Systemic Ca2+, mmol/l 1.16 (1.10–1.23) 1.16 (1.11–1.21) 0.995
Total Calcium, mmol/l 2.33 (2.20–2.50) 2.33 (2.21–2.45) 0.474
Calcium Ratio 1.95 (1.84–2.09) 1.98 (1.89–2.09) 0.296
Circuit Ca2+, mmol/l 0.37 (0.32–0.40) 0.42 (0.36–0.47) <0.001
Sodium, mmol/l 134 (133–136) 134 (132–135) 0.213
Potassium, mmol/l 4.2 (4.0–4.3) 4.2 (4.0–4.4) 0.159
Phosphate, mmol/l 0.70 (0.50–1.00) 1.20 (0.97–1.45) <0.001
Magnesium, mmol/l 0.78 (0.58–0.95) 0.79 (0.73–0.84) <0.001
pH, units 7.40 (7.36–7.44) 7.43 (7.40–7.46) <0.001
Bicarbonate, mmol/l 22.1 (20.9–23.5) 25.3 (23.8–26.6) <0.001
Base Excess −3.1 (−4.6 to −1.1) 0.9 (−0.8 to 2.4) <0.001
pCO2, mmHg 35 (32–41) 38 (35–40) 0.527
Apparent strong ion difference (AppSID), mEq/l 37.6 (36.1–39.4) 39.1 (37.9–40.2) <0.001
Effective strong ion difference (EffSID), mEq/l 32.0 (30.6–33.1) 34.3 (32.8–35.9) <0.001
Strong ion gap (SIG), mEq/l 5.8 (3.5–7.7) 4.5 (3.1–6.9) 0.585
Lactate, mmol/l 1.2 (0.9–1.6) 1.1 (0.8–1.4) <0.001
Platelet count, ×103/μl 90 (53–156) 187 (121–261) <0.001
Antithrombin III activity,% 72 (62–81) 75 (63–89) 0.078
aPTT Ratio 1.4 (1.3–1.6) 1.4 (1.2–1.7) 0.575
Supplementation needs
CaCl2 infusion, mmol/h 2.18 (1.90–2.45) 2.24 (1.97–2.58) 0.800
KCl infusion, mmol/h 5 (3–7) 2 (0–4) <0.001
Magnesium Sulphate, g/day 3 (2–3) 3 (3–3) <0.001
Need for bicarbonate infusion, n (%) 18/20 (90%) 0/20 (0%) <0.001
Infusion rate, mmol/h 6 ± 6.4 No supplementation
Need for phosphate supplementation, n (%) 20/20 (100%) 6/20 (30%) <0.001
g of phosphorus/day 3.39 ± 2.45 0.52 ± 1.53
Data are expressed as median (IQR) or mean ± SD or percentage.
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http://www.biomedcentral.com/1471-2369/14/232infusion of a highly concentrated bicarbonate solution
(8.4%) to obtain a more positive buffers balance [39].
However, other authors obtained an appropriate acid–base
balance with the use of a slightly higher concentration cit-
rate solution (13.3 mmol/l), without the need of additional
bicarbonate infusion [40,41].
In the present study, the adoption of an 18 mmol/l cit-
rate solution (protocol B) allowed to more efficiently meet
patient’ buffer requirements maintaining, at the same
time, a citrate load comparable to protocol A. Indeed, in
the protocol B patients, acid–base status was adequately
maintained without additional interventions and both
serum bicarbonate levels and pH values were significantly
higher to that achieved, despite bicarbonate infusion, in
patients undergoing RCA-CVVH with protocol A.
The use of an 18 mmol/l citrate solution is not new and
has been previously introduced in CVVHDF by Tolwani
et al. [22]. Comparing two different citrate solutions duringRCA, with the aim to optimize buffers mass balance, the
Authors found that the adoption of a citrate concentration
of 23 mmol/l was associated with a high incidence of meta-
bolic alkalosis (18 out of 24 patients) while the use of an
18 mmol/l solution was able to provide an appropriate
acid–base balance in most of the patients, although at some
point during CRRTalkalosis still occurred in 9 out of 32 pa-
tients. However, both protocols required a custom-made
dialysate with a lower than usual bicarbonate concentration
(25 mmol/l) [22]. These findings raised our attention about
the risk of alkalosis, possibly enhanced by the standard bi-
carbonate CRRT solution (30 mmol/l) adopted in protocol
B as dialysate and post-dilution replacement fluid. There-
fore, in order to prevent buffers overload related to
the combination of the solutions adopted, we accepted a
higher than usual c-Ca2+ target (≤0.5 mmol/l) with the
aim to minimize the need for any increment of citrate
dose throughout RCA-CRRT days. Thus, despite initial
Figure 4 Main acid–base parameters throughout RCA-CRRT days with the two different protocols. Data for protocol A (left panels) and
protocol B (right panels) are displayed as median and interquartile range (q1 to q3). * p < 0.05, ** p < 0.02, *** p < 0.001.
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http://www.biomedcentral.com/1471-2369/14/232concerns, protocol B afforded an appropriate acid–base bal-
ance without occurrence of clinically significant metabolic
alkalosis. In summary, although these findings need to be
confirmed in a more consistent number of patients and in
a wider range of clinical situations, the solutions combin-
ation adopted in protocol B appears to be at low risk of
acid–base derangements and represents, in our opinion, a
step forward if compared to protocol A.By shifting to protocol B, our purpose was also to sim-
plify RCA-CRRT handling and to reduce the need for
additional infusions. In particular, we aimed at minimiz-
ing CRRT-induced phosphate depletion [42] through the
combination of the citrate solution with a recently intro-
duced, commercially available, phosphate-containing
CRRT solution, acting as dialysate and post-dilution re-
placement fluid. In this regard, although the prognostic
Figure 5 Serum phosphate and need for phosphorus supplementation throughout RCA-CRRT days with the two different protocols.
Data for protocol A (left panel) and protocol B (right panel) are displayed as median and interquartile range (q1 to q3). *** p < 0.001.
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http://www.biomedcentral.com/1471-2369/14/232significance of mild to moderate serum phosphate dis-
turbances in critically ill patients is still a matter of
discussion [43], it is well known that severe hypopho-
sphatemia can cause generalized muscle weakness and
even paralysis of the respiratory muscles, myocardial
dysfunction, reduced peripheral vascular resistance and
encephalopathy [44]. Therefore, in patients undergoing
CRRT, it could be appropriate to prevent hypophospha-
temia by addition of phosphate to the replacement and/
or dialysate solutions. To this purpose, the feasibility
and safety of phosphate addition to conventional dialys-
ate and replacement fluids have been successfully tested
in adult and pediatric patients undergoing CRRT
[25,28]. More recently, the efficacy of a commercially
available phosphate-containing solution in preventing
hypophosphatemia has been reported in patients un-
dergoing CVVHDF [30] or CVVH [31]. However,
Chua et al. underlined that the switch to a phosphate-
containing solution as the sole replacement fluid for
CVVH could contribute to mild hyperphosphatemia and
could be associated with metabolic acidosis, possibly re-
lated to fluid composition [32]. In our RCA-CVVHDF
protocol, we adopted the same phosphate-containing so-
lution but it accounted for about 50% of total CRRT
dose and, as discussed above, its adoption in combin-
ation with an 18 mmol/l citrate solution was not associ-
ated with acid–base derangements. Furthermore, as
intended, the introduction of the phosphate-containing
solution appeared effective to prevent hypophosphate-
mia in 70% of protocol B patients; in the remaining
cases, the occurrence of a mild to moderate hypopho-
sphatemia was easily overwhelmed by an amount of
phosphorus supplementation much lower than that con-
stantly required in all patients undergoing RCA-CVVH
with protocol A. In addition, serum phosphate wassignificantly higher in protocol B patients and appeared
to be steadily maintained in a narrower range through-
out the entire RCA-CVVHDF treatment period without
occurrence of clinically relevant hyperphosphatemia. On
the contrary, as documented by the presence of hypo-
phosphatemia in more than 40% of determinations, the
strategy of parenteral phosphorus supplementation
adopted for protocol A was associated with wide-ranging
variations of phosphatemia during RCA-CVVH. These
findings confirm the efficacy of phosphate-containing
solutions in reducing the incidence of CRRT-induced
hypophosphatemia, already reported elsewhere during
conventional CRRT [25,28,30,31], adding useful informa-
tion about its use in the context of RCA and extending
the results of a single-case preliminary experience re-
cently reported by our own group [24]. Lastly, in com-
parison to most of the protocols reported elsewhere, the
adoption of a calcium-containing CRRT solution, which
characterizes both protocols, allowed us to reduce CaCl2
infusion requirement and to minimize the risk of errors
in bags handling related to the use of “zero” calcium
solutions.
Conclusions
In conclusion, the proposed RCA-CVVHDF protocol,
using an 18 mmol/l citrate solution, provided a more ad-
equate control of acid–base status if compared to the pre-
viously adopted 12 mmol/l RCA-CVVH protocol. The
adoption of a low citrate dose, particularly useful in pa-
tients with high severity scores, and the maintenance of a
higher than usual target circuit Ca2+ were still associated
with an adequate circuit lifetime and with a very low inci-
dence of clotting as cause of CRRT stopping. Finally, the
novel adoption of a phosphate-containing solution, in the
setting of RCA, allowed to prevent CRRT-induced
Morabito et al. BMC Nephrology 2013, 14:232 Page 11 of 12
http://www.biomedcentral.com/1471-2369/14/232hypophosphatemia in most of the patients, minimizing the
need for phosphorus supplementation.
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